Navigation Links
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
Date:12/21/2007

otech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the Phase 1a/Ib U.K. combination REOLYSIN(R) and radiation clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
(Date:9/16/2014)... YORK , Sept. 16, 2014 This report ... the following Product Segments: Software, Hardware, and Biocontent. The report ... , Japan , Europe ... America , and Rest of World. Annual estimates and ... a seven-year historic analysis is provided for these markets. Market ...
(Date:9/16/2014)... emerging field of molecular electronics could take our ... the construction of tiny circuits from molecular components. ... take on the roles currently played by comparatively-bulky ... researchers from five Japanese and Taiwanese universities has ... electronics: a molecule called picene. In a paper ...
(Date:9/16/2014)... BlueInGreen® , a water quality ... delivering dissolved gases into liquids, announced the addition ... manufacturer’s representative firm to its sales network. H2Flow ... water and wastewater applications in the Canadian provinces ... in 1992 and serves Quebec and Ontario markets ...
Breaking Biology Technology:Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... This release is available in German . ... magic word in electronics. Dr. Willi Auwaerter and Professor Johannes ... Universitaet Muenchen (TUM), have now presented a novel molecular switch ... functionality of the switch is the position of a single ...
... Therapeutics, Inc. today announced that Ivan Bergstein, MD, the ... the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December ... Astoria Hotel in New York City. ... Inc. is a clinical stage biopharmaceutical company developing novel ...
... 2011 Syndax Pharmaceuticals, Inc. announced today ... study, demonstrated entinostat, a novel, oral small molecule inhibitor ... single agent in patients with relapsed or refractory Hodgkin,s ... 11, from 6:00 to 8:00 PM PT at the ...
Cached Biology Technology:The smallest conceivable switch 2Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/16/2014)... Center for Children,s Environmental Health at the Mailman School ... association between childhood asthma and prenatal exposure to two ... Results appear online in the journal Environmental Health ... during pregnancy to higher levels of the chemicals, butylbenzyl ... percent and 78 percent increase in risk of developing ...
(Date:9/16/2014)... on September 13, 2014. The fire is human-caused and ... 2,300 acres in size and is mostly being fueled ... calm Monday night due to higher humidity. Yesterday ... beginning to construct a fireline on the West and North ... on the fire: , 7 20-person Crews, 4 Hot Shot ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... launched a key initiative to keep Europe at the forefront ... cell therapies to restore lost, damaged, or ageing cells and ... body,s ,master cells, that have not yet been programmed to ... of stem cells, and it is becoming clear that if ...
... (TWIC) Program, Ensures No Fraudulent Duplicate Enrollments ... Fla., June 17 ID Solutions, Inc., ... trusted,credential assurance, reported that it has been ... the Transportation Security Agency,s (TSA,s),TWIC program. The ...
... its latest state of the environment report, released ... environmental issues facing the NAFTA partners. The ... biodiversity and ecosystems, and pollution. Specific topics include ... vaquita porpoiseand the quality and quantity of water ...
Cached Biology News:European Science Foundation aims to strengthen 'regenerative medicine' 2ID Solutions Awarded Full-Production Order for Fingerprint Processing Software for TWIC 2New report looks at the state of the North American environment 2
... precision pressure regulator and pressurized syringe holder for ... Steady flow rate Microinjecting Fine ... Can be added to any new or existing ... manufacturer, even homemade. Connect to house air or ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: